Effective chimeric antigen receptor T cells against SARS-CoV-2

Current therapies to treat coronavirus disease 2019 (COVID-19) involve vaccines against the spike protein S1 of SARS-CoV-2. Here, we outline an alternative approach involving chimeric antigen receptors (CARs) in T cells (CAR-Ts). CAR-T recognition of the SARS-CoV-2 receptor-binding domain (RBD) pept...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xueyang, Kazanova, Alexandra, Thurmond, Stephanie, Saragovi, H. Uri, Rudd, Christopher E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520176/
https://www.ncbi.nlm.nih.gov/pubmed/34693218
http://dx.doi.org/10.1016/j.isci.2021.103295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520176/
https://www.ncbi.nlm.nih.gov/pubmed/34693218
http://dx.doi.org/10.1016/j.isci.2021.103295

Ejemplares similares